Jon Snodgres - Repligen Chief Officer
| RGEN Stock | USD 146.06 3.48 2.44% |
Executive
Mr. Jon K. Snodgres is Chief Financial Officer of the Company. Mr. Snodgres joins Repligen from his CFO role at Maquet Cardiovascular, a medical device company. Over the course of five years with Maquet, Mr. Snodgres contributed to the company growth from niche status to a diversified business generating over 1 billion in annual revenue. Mr. Snodgres previously spent eight years with life sciences company Thermo Fisher Scientific where he was Vice President of Finance for the Laboratory Products Group. At both Maquet and Thermo Fisher, Mr. Snodgres held key responsibility for numerous acquisitions and restructuring programs. He was also integral to the success of pricing and facility optimization programs that drove substantial earnings improvements. Mr. Snodgres joined Maquet Cardiovascular as CFO in 2009. There, in addition to PL, balance sheet and cash flow responsibility, he was a key participant in growth planning and profit improvement strategies. During his tenure with Maquet, the company cardiovascular business significantly increased sales and earnings through acquisitions, organic growth, portfolio management, pricing discipline and restructuring actions. While with Thermo Fisher Scientific, as Laboratory Products Group Vice President of Finance from 2005 to 2008, Mr. Snodgres helped drive profit improvements through acquisition, consolidation and facility optimization, as well as the implementation of analytical tools and processes that enhanced decision making. Mr. Snodgres has also served as Vice President of Financial Operations for Newport Corporationrationration, a laser and photonics solutions provider. He began his career in finance at AlliedSignalHoneywell International since 2014.
| Age | 58 |
| Tenure | 10 years |
| Address | Building 1, Waltham, MA, United States, 02453 |
| Phone | 781 250 0111 |
| Web | https://www.repligen.com |
Jon Snodgres Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jon Snodgres against Repligen stock is an integral part of due diligence when investing in Repligen. Jon Snodgres insider activity provides valuable insight into whether Repligen is net buyers or sellers over its current business cycle. Note, Repligen insiders must abide by specific rules, including filing SEC forms every time they buy or sell Repligen'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jon Snodgres over a year ago Payment of 710 shares by Jon Snodgres of Repligen subject to Rule 16b-3 | ||
Jon Snodgres over a year ago Acquisition by Jon Snodgres of 4848 shares of Repligen subject to Rule 16b-3 | ||
Jon Snodgres over a year ago Payment of 521 shares by Jon Snodgres of Repligen subject to Rule 16b-3 | ||
Jon Snodgres over a year ago Payment of 682 shares by Jon Snodgres of Repligen subject to Rule 16b-3 |
Repligen Management Efficiency
As of the 25th of November 2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.02. At this time, Repligen's Intangible Assets are very stable compared to the past year. As of the 25th of November 2024, Net Tangible Assets is likely to grow to about 847.1 M, while Deferred Long Term Asset Charges is likely to drop about 2.2 M. Repligen's management efficiency ratios could be used to measure how well Repligen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Benjamin Cohn | Hologic | N/A | |
| Laura Piccinini | AngioDynamics | 55 | |
| Nicholas JD | The Cooper Companies, | 50 | |
| Christopher Carlson | Intuitive Surgical | N/A | |
| Marna BronfenMoore | AngioDynamics | 57 | |
| Marry Skafidas | AptarGroup | N/A | |
| Paul Sumilas | Envista Holdings Corp | N/A | |
| Brian JD | Merit Medical Systems | 63 | |
| Elizabeth McCombs | Becton Dickinson and | 48 | |
| Karleen CPA | Hologic | 54 | |
| JoAnne Alkire | Merit Medical Systems | N/A | |
| Stephen Keller | Envista Holdings Corp | 50 | |
| John CFA | West Pharmaceutical Services | N/A | |
| Kerri DiPietro | Haemonetics | N/A | |
| John Griffin | Hologic | 63 | |
| Filippo Impieri | Envista Holdings Corp | N/A | |
| Robert DeSantis | Intuitive Surgical | 58 | |
| Henry Charlton | Intuitive Surgical | 54 | |
| Scott Centea | AngioDynamics | 45 | |
| Hemanth Reddy | ResMed Inc | N/A | |
| Shiela Vinczeller | AptarGroup | 60 | |
Management Performance
| Return On Equity | -0.001 | ||||
| Return On Asset | 0.002 |
Repligen Leadership Team
Elected by the shareholders, the Repligen's board of directors comprises two types of representatives: Repligen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Repligen. The board's role is to monitor Repligen's management team and ensure that shareholders' interests are well served. Repligen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Repligen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine Gebski, Senior Chromatography | ||
| Kimberly Cornwell, General Counsel | ||
| Dianne Heiler, Senior Sustainability | ||
| James Bylund, Chief Officer | ||
| Kola Otitoju, Senior Development | ||
| Stephen Tingley, VP Sales | ||
| Jaime Humara, Senior Marketing | ||
| Jon Snodgres, Chief Officer | ||
| Olivier Loeillot, President Officer | ||
| Rachel Goodrich, VP Marketing | ||
| Ralf Kuriyel, Senior Vice President - Research & Development | ||
| Neil Whitfield, Vice Sales | ||
| Leslie Galvin, Global Resources | ||
| Mark Salerno, VP Analytics | ||
| Keith Robinson, Chief Officer | ||
| Sondra Newman, Global Relations | ||
| Jason Garland, Chief Officer | ||
| Anthony Hunt, President CEO, Director | ||
| Teresa Ferragamo, Senior Marketing | ||
| Craig Harrison, VP Analytics |
Repligen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Repligen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.001 | ||||
| Return On Asset | 0.002 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 7.88 B | ||||
| Shares Outstanding | 56.03 M | ||||
| Shares Owned By Insiders | 6.56 % | ||||
| Shares Owned By Institutions | 93.44 % | ||||
| Number Of Shares Shorted | 3.3 M | ||||
| Price To Earning | 154.58 X |
Pair Trading with Repligen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Repligen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Repligen will appreciate offsetting losses from the drop in the long position's value.Moving against Repligen Stock
The ability to find closely correlated positions to Repligen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Repligen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Repligen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Repligen to buy it.
The correlation of Repligen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Repligen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Repligen moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Repligen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.83) | Earnings Share (0.03) | Revenue Per Share 11.452 | Quarterly Revenue Growth 0.097 | Return On Assets 0.002 |
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.